Esperion Therapeutics Inc. (NASDAQ:ESPR) has a beta value of 1.02 and has seen 9.94 million shares traded in the last trading session. The company, currently valued at $398.78M, closed the last trade at $2.34 per share which meant it gained $0.12 on the day or 5.41% during that session. The ESPR stock price is -45.3% off its 52-week high price of $3.40 and 70.09% above the 52-week low of $0.70. The 3-month trading volume is 8.70 million shares.
Esperion Therapeutics Inc. (NASDAQ:ESPR) trade information
Sporting 5.41% in the green in last session, the stock has traded in the green over the last five days, when the ESPR stock price touched $2.34 or saw a rise of 11.7%. Year-to-date, Esperion Therapeutics Inc. shares have moved -21.74%, while the 5-day performance has seen it change 7.34%. Over the past 30 days, the shares of Esperion Therapeutics Inc. (NASDAQ:ESPR) have changed 2.18%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Esperion Therapeutics Inc. (ESPR) estimates and forecasts
Figures show that Esperion Therapeutics Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -24.03% over the past 6 months, with this year growth rate of 95.57%, compared to 13.40% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 23.09% over the past 5 years. Earnings growth for 2024 is a modest 100.30% while over the next 5 years, the company’s earnings are expected to increase by 16.90%.
ESPR Dividends
Esperion Therapeutics Inc. is expected to release its next earnings report in August this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
